Photo Credit:
Offices of Teva and Allergan.

The Israeli-based Teva Pharmaceutics company is going to shell out $40.5 billion to buy Allergan and withdraw a troubled offer for almost the same amount of money to purchase Mylan, according to financial media reports Monday morning.

Mylan has opposed the offer, and Teva’s buying Allergan would extricate it from a bitter battle for Mylan. The addition of Allergan also would strongly strengthen Teva’s generic drug position in the industry.

Advertisement




Teva’s share price leaped 10% in trading in Tel Aviv Monday morning after trading has been suspended pending a “significant” announcement by the company.

Teva’s attempt to buy Mylan turned out to be a hostile takeover attempt that has resulted in a nasty war of words between the two companies. Indications are that the stock will open 25% higher than last week’s close.

Mylan chairman Robert Coury has called Teva’s bid “not even close to qualifying as a proposal worth pursuing,” while Teva countered that the purchase would expose Mylan as a “dysfunctional culture” and “troubled company.”

Advertisement

SHARE
Previous articleMedical Marijuana to be Available at Pharmacies
Next articleFROM TEHERAN TO UNRWA: The New US-UNRWA Accord
Tzvi Ben Gedalyahu is a graduate in journalism and economics from The George Washington University. He has worked as a cub reporter in rural Virginia and as senior copy editor for major Canadian metropolitan dailies. Tzvi wrote for Arutz Sheva for several years before joining the Jewish Press.